Paper32937743
Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study.
Caccese M and 12 others. Int J Mol Sci, 2020. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study. Papers, record 32937743. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32937743
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA Mismatch Repair | Major topic |
| DNA-Binding Proteins | Major topic |
| Glioma | Major topic |
| Adult | |
| Aged | |
| Biomarkers, Tumor | |
| Female | |
| Humans | |
| Immunohistochemistry | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Retrospective Studies |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35427471 | Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/35427471 | PubMed |
| 2 | 28371827 | Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. | Neuro Oncol | 2017 | https://conductscience.org/library/papers/28371827 | PubMed |
| 3 | 21425258 | Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. | Int J Cancer | 2011 | https://conductscience.org/library/papers/21425258 | PubMed |
| 4 | 30514778 | Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30514778 | PubMed |
| 5 | 31480372 | Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31480372 | PubMed |
| 6 | 20223108 | The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. | Neurol Res | 2010 | https://conductscience.org/library/papers/20223108 | PubMed |
| 7 | 19584161 | MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19584161 | PubMed |
| 8 | 29020592 | First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. | N Engl J Med | 2017 | https://conductscience.org/library/papers/29020592 | PubMed |
| 9 | 10362805 | High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. | Am J Pathol | 1999 | https://conductscience.org/library/papers/10362805 | PubMed |
| 10 | 28596308 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Science | 2017 | https://conductscience.org/library/papers/28596308 | PubMed |
| 11 | 31765263 | Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31765263 | PubMed |
| 12 | 32823925 | Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32823925 | PubMed |
| 13 | 26028255 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26028255 | PubMed |
| 14 | 32437507 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32437507 | PubMed |
| 15 | 32051040 | The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. | Acta Neuropathol Commun | 2020 | https://conductscience.org/library/papers/32051040 | PubMed |
| 16 | 30813960 | The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/30813960 | PubMed |
| 17 | 31682550 | Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31682550 | PubMed |
| 18 | 29355075 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29355075 | PubMed |
| 19 | 19228619 | IDH1 and IDH2 mutations in gliomas. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19228619 | PubMed |
| 20 | 27157931 | The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. | Acta Neuropathol | 2016 | https://conductscience.org/library/papers/27157931 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42511857 | Divergent Roles of Canonical and Non-Canonical Mismatch Repair in Regulating Temozolomide Sensitivity in Glioblastoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511857 | PubMed |
| 42416056 | Identification and validation of biomarkers related to mismatch repair for prognosis prediction in glioma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42416056 | PubMed |
| 42344520 | The relationship between DNA damage and repair and the occurrence and development of disease. | Front Genet | 2026 | https://conductscience.org/library/papers/42344520 | PubMed |
| 41615212 | Overcoming Intrinsic and Acquired Temozolomide Resistance in Glioblastoma: Fisetin as a Potential Strategy to Enhance Sensitivity via ZEB1 Modulation. | Turk J Pharm Sci | 2026 | https://conductscience.org/library/papers/41615212 | PubMed |
| 41395548 | Comparative molecular analysis of primary and recurrent pleomorphic xanthoastrocytoma with BRAF mutation treated with combination therapy with dabrafenib and trametinib: a case report and literature review. | Int Cancer Conf J | 2025 | https://conductscience.org/library/papers/41395548 | PubMed |
| 41340766 | Mismatch Repair Deficiency in Gliomas: A Rare Insight into Microsatellite Instability and Its Diagnostic Implications. | Asian J Neurosurg | 2025 | https://conductscience.org/library/papers/41340766 | PubMed |
| 41233526 | Huntington disease: somatic expansion, pathobiology and therapeutics. | Nat Rev Neurol | 2026 | https://conductscience.org/library/papers/41233526 | PubMed |
| 40302099 | Correlation between Isocitrate Dehydrogenase Mutation and Immunohistochemical Expression of DNA Mismatch Repair Proteins in the Prognosis of Gliomas. | Asian Pac J Cancer Prev | 2025 | https://conductscience.org/library/papers/40302099 | PubMed |
| 38897003 | Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity. | DNA Repair (Amst) | 2024 | https://conductscience.org/library/papers/38897003 | PubMed |
| 38786078 | Prime Editing and DNA Repair System: Balancing Efficiency with Safety. | Cells | 2024 | https://conductscience.org/library/papers/38786078 | PubMed |
| 38749429 | Therapeutic validation of MMR-associated genetic modifiers in a human ex vivo model of Huntington disease. | Am J Hum Genet | 2024 | https://conductscience.org/library/papers/38749429 | PubMed |
| 37529690 | Characteristics of glioblastomas and immune microenvironment in a Chinese family with Lynch syndrome and concurrent porokeratosis. | Front Oncol | 2023 | https://conductscience.org/library/papers/37529690 | PubMed |
| 35865481 | PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/35865481 | PubMed |
| 35332262 | Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas. | Lab Invest | 2022 | https://conductscience.org/library/papers/35332262 | PubMed |
| 34944798 | Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944798 | PubMed |
| 34848827 | Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors. | Lab Invest | 2022 | https://conductscience.org/library/papers/34848827 | PubMed |
| 34638714 | Prognostic and Predictive Biomarkers in Gliomas. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34638714 | PubMed |
| 34620200 | Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/34620200 | PubMed |
| 33375286 | Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33375286 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 | NCBI Gene |
| MLH1 | 4292 | PubTator's text mining | https://conductscience.org/library/genes/4292 | NCBI Gene |
| MSH2 | 4436 | PubTator's text mining | https://conductscience.org/library/genes/4436 | NCBI Gene |
| MSH6 | 2956 | PubTator's text mining | https://conductscience.org/library/genes/2956 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| PMS2 | 5395 | PubTator's text mining | https://conductscience.org/library/genes/5395 | NCBI Gene |
| SPATA2 | 9825 | PubTator's text mining | https://conductscience.org/library/genes/9825 | NCBI Gene |
| TGFBR2 | 7048 | PubTator's text mining | https://conductscience.org/library/genes/7048 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32937743
GET https://conductscience.org/api/papers/v1/32937743/references?page=2